Pfizer announces approval of Ibrance is getting closer
A targeted therapy for HER2 negative breast cancer is going to be introduced in Korea.
According to the industry concerned on the 16th, a Pfizer Pharmaceuticals Korea’s new breast cancer therapy, ‘Ibrance(palbociclib),’ is expected to acquire approval in the second half of the year.
Generally...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
